Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Target Price at $243.59

IQVIA Holdings Inc. (NYSE:IQV) has been assigned a consensus rating of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $243.1875.

Several equities research analysts have recently issued reports on the company. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and raised their price objective for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Stifel Nicolaus boosted their price objective on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Finally, Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd.

IQVIA Price Performance

Shares of IQVIA stock opened at $225.05 on Wednesday. The firm has a market cap of $38.33 billion, a PE ratio of 30.84, a PEG ratio of 2.52 and a beta of 1.37. The stock has a 50 day moving average of $219.88 and a 200 day moving average of $193.90. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA has a 12 month low of $134.65 and a 12 month high of $234.29.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same period in the prior year, the firm earned $2.84 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of IQVIA by 3.5% in the 1st quarter. Public Sector Pension Investment Board now owns 21,112 shares of the medical research company’s stock valued at $3,722,000 after acquiring an additional 717 shares during the period. Algert Global LLC purchased a new stake in shares of IQVIA during the 1st quarter worth $443,000. Wellington Management Group LLP grew its stake in IQVIA by 232.4% in the first quarter. Wellington Management Group LLP now owns 32,542 shares of the medical research company’s stock valued at $5,737,000 after purchasing an additional 22,751 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in IQVIA by 29.8% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 6,179 shares of the medical research company’s stock worth $1,089,000 after purchasing an additional 1,420 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.